Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-02-23 08:30:00
Cline Scientific AB (publ) ("Cline" or the "Company") issues the following bokslutskommuniké for 2023.
- Net sales amounted to SEK 0 (0).
- Operating profit amounted to SEK 240,145 (237,140).
- Profit per average number of shares after tax amounted to 0.01 (0.01)
- Net sales amounted to SEK 0 (0).
- Operating profit amounted to SEK -3,108,861 (-2,317,061)
- Profit per average number of shares after tax amounted to -0.10 (-0.15)
The report is published at www.clinescientific.com/financial-reports
For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088
The company is listed on the Nasdaq First North Growth Market. Redeye AB is Cline Scientific's Certified Adviser. The information was submitted for publication via the contact person listed above, at 8.30am CET on 23 February 2024.